Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Total Non-Current Liabilities (2020 - 2025)

Maxcyte (MXCT) has disclosed Total Non-Current Liabilities for 6 consecutive years, with $30.8 million as the latest value for Q4 2025.

  • Quarterly Total Non-Current Liabilities fell 6.65% to $30.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $30.8 million through Dec 2025, down 6.65% year-over-year, with the annual reading at $30.8 million for FY2025, 6.65% down from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $30.8 million at Maxcyte, down from $33.2 million in the prior quarter.
  • The five-year high for Total Non-Current Liabilities was $35.8 million in Q4 2023, with the low at $13.1 million in Q3 2021.
  • Average Total Non-Current Liabilities over 5 years is $28.9 million, with a median of $31.0 million recorded in 2024.
  • The sharpest move saw Total Non-Current Liabilities skyrocketed 144.74% in 2022, then decreased 10.1% in 2023.
  • Over 5 years, Total Non-Current Liabilities stood at $20.8 million in 2021, then surged by 50.99% to $31.4 million in 2022, then grew by 14.22% to $35.8 million in 2023, then decreased by 8.04% to $32.9 million in 2024, then decreased by 6.65% to $30.8 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $30.8 million, $33.2 million, and $28.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.